What is the role of TAK-285 in targeting HER2 and EGFR in cancer treatment?
Label:chem
Topic
TAK-285 is a novel low-molecular weight compound designed to selectively and potently inhibit HER2 and EGFR kinase activities. HER2 and EGFR are members of the human epidermal growth factor receptor (EGFR) protein family, and their overexpression is associated with aggressive cancer types such as breast, gastric, colon, ovarian, and bladder cancers.
Answer
TAK-285 inhibits HER2 and EGFR phosphorylation, with 50% inhibition concentrations of 17 and 23 nmol l–1, respectively. It has been shown to effectively inhibit the growth of HER2- or EGFR-overexpressing human tumor xenografts in murine models. TAK-285 also demonstrated potentially no exhibition of elevated cardiac risks, unlike other tyrosine kinase inhibitors that can elicit secondary effects including heart toxicity.
Return to Home
Chemical List
Knowledge you may be interested in